{"id":12648,"date":"2021-07-13T18:01:28","date_gmt":"2021-07-13T12:31:28","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=12648"},"modified":"2021-07-24T12:58:29","modified_gmt":"2021-07-24T07:28:29","slug":"pharma-happenings-for-jnj-bayer-novo-prothena","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-jnj-bayer-novo-prothena","title":{"rendered":"Bayer&#8217;s CKD Drug;  Enochian\u2019s RNA Hijack for HBV; Novo Nordisk&#8217;s to get Prothena&#8217;s ATTR Amyloidosis Business; J&#038;J\u2019s COVID-19 Vaccine Struggle"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a42f76f103a8\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a42f76f103a8\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-jnj-bayer-novo-prothena\/#Bayer_Scores_FDA-Approval_for_its_CKD_Drug_Finerenone\" >Bayer Scores FDA-Approval for its CKD Drug Finerenone<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-jnj-bayer-novo-prothena\/#FDA_Accepts_Pre-IND_Request_for_Enochians_RNA_Treatment_for_HBV\" >FDA Accepts Pre-IND Request for Enochian\u2019s RNA Treatment for HBV<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-jnj-bayer-novo-prothena\/#Novo_Nordisk_is_Footing_the_Bill_for_Prothenas_ATTR_Amyloidosis_Business\" >Novo Nordisk is Footing the Bill for Prothena&#8217;s ATTR Amyloidosis Business&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-jnj-bayer-novo-prothena\/#A_New_Warning_for_J_Js_COVID-19_Vaccine_Due_to_a_Rare_Neurological_Disorder\" >A New Warning for J&amp;J\u2019s COVID-19 Vaccine; Due to a Rare Neurological Disorder&nbsp;&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bayer_Scores_FDA-Approval_for_its_CKD_Drug_Finerenone\"><\/span><strong>Bayer Scores FDA-Approval for its CKD Drug Finerenone<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Following a priority review, the USFDA finally gave its thumbs-up to Bayer AG\u2019s Kerendia (finerenone) for chronic kidney disease (CKD) associated with type 2 diabetes (T2D) based on the results from the Phase III <strong>FIDELIO-DKD <\/strong>study.<\/p>\n\n\n\n<p>Finerenone is the first and only non-steroidal mineralocorticoid receptor antagonist (MRA), which works by blocking the overactivation of the mineralocorticoid receptor that is associated with fibrosis and inflammation leading to permanent structural kidney damage.&nbsp;<\/p>\n\n\n\n<p>The drug managed to improve cardiovascular and kidney outcomes by reducing the risk of kidney failure, heart attack, heart failure hospitalization, and cardiovascular death.&nbsp;<\/p>\n\n\n\n<p>However, after receiving the approval, competing in the market against AstraZeneca and Johnson &amp; Johnson might prove to be another uphill task. Even so, around 40% of Type 2 diabetes patients in the U.S. ultimately develop <a href=\"https:\/\/www.delveinsight.com\/report-store\/moderate-and-severe-chronic-kidney-disease-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">chronic kidney disease<\/a>, Bayer has a huge patient pool to cater to, which will add to the revenues of the company.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-accepts-pre-ind-request-for-enochian-s-rna-treatment-for-hbv\"><span class=\"ez-toc-section\" id=\"FDA_Accepts_Pre-IND_Request_for_Enochians_RNA_Treatment_for_HBV\"><\/span><strong>FDA Accepts Pre-IND Request for Enochian\u2019s RNA Treatment for HBV<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Enochian Biosciences announced the FDA acceptance of a Pre-IND (Investigational New Drug) request for a potential cure of <a href=\"https:\/\/www.delveinsight.com\/report-store\/hepatitis-b-virus-hbv-infection-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">hepatitis B virus (HBV) infection<\/a>.<\/p>\n\n\n\n<p>Enochian Biosciences is a biopharma firm and is leveraging a novel mechanism, known as Hijack RNA, to target coronaviruses, including the cause of COVID-19, influenza, HBV, and HIV.&nbsp;<\/p>\n\n\n\n<p>The company is encouraged by the results and pronounces that its innovative cellular Hijack RNA therapy tricks the virus to use certain proteins leading to the death of infected cells instead of reproducing more viral cells. The decision came after the potential data submitted to the USFDA from a proof-of-concept study conducted in chimeric mice, the \u2018gold standard\u2019 animal model to evaluate HBV cure, as referred by some scientists.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-novo-nordisk-is-footing-the-bill-for-prothena-s-attr-amyloidosis-business\"><span class=\"ez-toc-section\" id=\"Novo_Nordisk_is_Footing_the_Bill_for_Prothenas_ATTR_Amyloidosis_Business\"><\/span><strong>Novo Nordisk is Footing the Bill for Prothena&#8217;s ATTR Amyloidosis Business&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Novo Nordisk announced the acquisition of clinical-stage antibody <strong>PRX004 <\/strong>and <strong>ATTR amyloidosis programs<\/strong> of late-stage clinical firm Prothena Corporation in a deal that cost the company a sum of $1.2 billion.&nbsp;<\/p>\n\n\n\n<p>Under the terms of the definitive purchase agreement, Novo Nordisk will acquire complete business including but not limited to global intellectual property rights, Prothena&#8217;s<a href=\"https:\/\/www.delveinsight.com\/report-store\/transthyretin-amyloidosis-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\"> ATTR amyloidosis<\/a> business and pipeline. In return, Prothena gets to add USD 1.2 Bn and milestone payments ( $100 million in upfront and near-term clinical milestones payouts) to its wallet.<\/p>\n\n\n\n<p>Novo is primarily focused on developing drugs and therapies for <a href=\"https:\/\/www.delveinsight.com\/blog\/diabetes-types-risk-factors-and-treatment-options\/?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">diabetes<\/a>, however, the move to acquire ATTR amyloidosis therapies clearly depicts the goal of the company to foray and expand its portfolio in different markets, and seems like the company started with choosing the rare disease market.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-a-new-warning-for-j-j-s-covid-19-vaccine-due-to-a-rare-neurological-disorder\"><span class=\"ez-toc-section\" id=\"A_New_Warning_for_J_Js_COVID-19_Vaccine_Due_to_a_Rare_Neurological_Disorder\"><\/span><strong>A New Warning for J&amp;J\u2019s COVID-19 Vaccine; Due to a Rare Neurological Disorder&nbsp;&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>J&amp;J COVID-19 vaccine has always been in the news, be it due to J&amp;J\u2019s manufacturing deals and spree for vaccine or associated side effects of the vaccine. Earlier it was blood clots and now it is something more serious.&nbsp;&nbsp;<\/p>\n\n\n\n<p>The US drug regulatory agency issued a new warning for Johnson &amp; Johnson\u2019s COVID-19 vaccine linked to a rare and potentially severe neurological reaction in the patients. After the administration of the 12.8 million doses, approximately 100 reports of Guillain-Barr\u00e9 syndrome (GBS) were raised, stated the CDC after a period of two weeks mostly in men of age 50 and older.&nbsp;<\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/guillain-barre-syndrome-gbs-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">Guillain-Barr\u00e9 Syndrome<\/a> is a rare neurological disorder that is a result of the immune system attacking a part of the peripheral nervous system leading to muscle weakness, difficulty with eye muscles and vision, difficulty in swallowing, speaking, or chewing, needle-like sensations in the hands and feet, severe pain, particularly at night, abnormal heart rate or blood pressure, and problems with digestion and\/or bladder control. It can also lead to paralysis.&nbsp;<\/p>\n\n\n\n<p>The vaccine was highly sought-after owing to its single formulation and convenient storage &amp; handling; however, with early on reports of rare blood clots and now GBS, the picture for the J&amp;J\u2019s <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">Covid-19 vaccine<\/a> appears quite grim.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bayer Scores FDA-Approval for its CKD Drug Finerenone Following a priority review, the USFDA finally gave its thumbs-up to Bayer AG\u2019s Kerendia (finerenone) for chronic kidney disease (CKD) associated with type 2 diabetes (T2D) based on the results from the Phase III FIDELIO-DKD study. Finerenone is the first and only non-steroidal mineralocorticoid receptor antagonist (MRA), [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":12652,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1485,107,143,2815,15648,812,1572,2789],"industry":[17225],"therapeutic_areas":[17230,17231],"class_list":["post-12648","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-attr-amyloidosis","tag-bayer","tag-cardiovascular-disease","tag-chronic-kidney-disease-ckd","tag-covid-19-vaccines","tag-diabetes","tag-guillain-barre-syndrome","tag-jhonson-jhonsons","industry-pharmaceutical","therapeutic_areas-genito-urinary-system-and-sex-hormones","therapeutic_areas-infectious-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Bayer&#039;s CKD Drug Approval; New Warning for J&amp;J\u2019s COVID-19 Vaccine<\/title>\n<meta name=\"description\" content=\"Bayer&#039;s CKD Drug; Enochian\u2019s RNA Hijack for HBV; Novo Nordisk&#039;s to get Prothena&#039;s ATTR Amyloidosis Business; J&amp;J\u2019s COVID-19 Vaccine Struggle\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-jnj-bayer-novo-prothena\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer&#039;s CKD Drug Approval; New Warning for J&amp;J\u2019s COVID-19 Vaccine\" \/>\n<meta property=\"og:description\" content=\"Bayer&#039;s CKD Drug; Enochian\u2019s RNA Hijack for HBV; Novo Nordisk&#039;s to get Prothena&#039;s ATTR Amyloidosis Business; J&amp;J\u2019s COVID-19 Vaccine Struggle\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-jnj-bayer-novo-prothena\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-13T12:31:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/07\/13180043\/pharma-happenings-for-jnj-bayer-novo-prothena.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer's CKD Drug Approval; New Warning for J&J\u2019s COVID-19 Vaccine","description":"Bayer's CKD Drug; Enochian\u2019s RNA Hijack for HBV; Novo Nordisk's to get Prothena's ATTR Amyloidosis Business; J&J\u2019s COVID-19 Vaccine Struggle","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-jnj-bayer-novo-prothena","og_locale":"en_US","og_type":"article","og_title":"Bayer's CKD Drug Approval; New Warning for J&J\u2019s COVID-19 Vaccine","og_description":"Bayer's CKD Drug; Enochian\u2019s RNA Hijack for HBV; Novo Nordisk's to get Prothena's ATTR Amyloidosis Business; J&J\u2019s COVID-19 Vaccine Struggle","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-jnj-bayer-novo-prothena","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-07-13T12:31:28+00:00","article_modified_time":"2021-07-24T07:28:29+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/07\/13180043\/pharma-happenings-for-jnj-bayer-novo-prothena.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-jnj-bayer-novo-prothena","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-jnj-bayer-novo-prothena","name":"Bayer's CKD Drug Approval; New Warning for J&J\u2019s COVID-19 Vaccine","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-jnj-bayer-novo-prothena#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-jnj-bayer-novo-prothena#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/07\/13180043\/pharma-happenings-for-jnj-bayer-novo-prothena.jpg","datePublished":"2021-07-13T12:31:28+00:00","dateModified":"2021-07-24T07:28:29+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Bayer's CKD Drug; Enochian\u2019s RNA Hijack for HBV; Novo Nordisk's to get Prothena's ATTR Amyloidosis Business; J&J\u2019s COVID-19 Vaccine Struggle","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-jnj-bayer-novo-prothena"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-jnj-bayer-novo-prothena#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/07\/13180043\/pharma-happenings-for-jnj-bayer-novo-prothena.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/07\/13180043\/pharma-happenings-for-jnj-bayer-novo-prothena.jpg","width":772,"height":482,"caption":"pharma-happenings-for-jnj-bayer-novo-prothena"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/07\/13180043\/pharma-happenings-for-jnj-bayer-novo-prothena-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ATTR Amyloidosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bayer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cardiovascular disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chronic kidney disease (CKD)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Covid-19 vaccines<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Diabetes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Guillain Barre Syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Jhonson &amp; Jhonson\u2019s<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">ATTR Amyloidosis<\/span>","<span class=\"advgb-post-tax-term\">Bayer<\/span>","<span class=\"advgb-post-tax-term\">Cardiovascular disease<\/span>","<span class=\"advgb-post-tax-term\">Chronic kidney disease (CKD)<\/span>","<span class=\"advgb-post-tax-term\">Covid-19 vaccines<\/span>","<span class=\"advgb-post-tax-term\">Diabetes<\/span>","<span class=\"advgb-post-tax-term\">Guillain Barre Syndrome<\/span>","<span class=\"advgb-post-tax-term\">Jhonson &amp; Jhonson\u2019s<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jul 13, 2021","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jul 13, 2021 6:01 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"pharma-happenings-for-jnj-bayer-novo-prothena","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12648","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=12648"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12648\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/12652"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=12648"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=12648"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=12648"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=12648"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=12648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}